Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neoplasms 5Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Colorectal Neoplasms 2Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leiomyosarcoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Islet Cell 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

napabucasin 1irinotecan sucrosofate 1cixutumumab 1Taxes 1Sunitinib 1Paclitaxel 1Oxaliplatin 1Octreotide 1Melphalan 1Leucovorin 1Irinotecan 1Gemcitabine 1Fluorouracil 1Fentanyl 1Everolimus 1Albumin-Bound Paclitaxel 190Y-octreotide, DOTA-Tyr(3)- 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Islet Cell × cixutumumab × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡